Category Archives: Blog

The Benefits of Orphan Drug Designation and Market Exclusivity

Orphan Drug Designation (ODD) is one of the earliest and most essential regulatory steps for sponsors developing therapies for rare diseases. For eligible products, this designation opens the door to significant financial, regulatory, and strategic advantages that can shape the … Continue reading →

Posted in Blog | Comments Off on The Benefits of Orphan Drug Designation and Market Exclusivity

FDA Introduces Rare Disease Evidence Principles (RDEP) to Advance Orphan Drug Development

The FDA’s New Rare Disease Evidence Principles The U.S. Food and Drug Administration (FDA) has introduced the Rare Disease Evidence Principles (RDEP), a new framework designed to provide greater clarity and predictability for drug developers pursuing therapies for rare diseases. … Continue reading →

Posted in Blog | Comments Off on FDA Introduces Rare Disease Evidence Principles (RDEP) to Advance Orphan Drug Development